Anticoagulation management in patients with mechanical heart valve replacement: A case control study_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

LIN Meiqin ¹ , QIU Hanfan ² , XIE Xianbiao ² , CHEN Meilian ² ,  SONG Hongtao ¹

1. Department of Pharmacy, Fuzhou General Hospital, Fuzhou,350025, P.R.China;
2. Department of Cardiac Surgery, Fujian Medical University Union Hospital, Fuzhou, 350025, P.R.China;

Corresponding?author：

SONG Hongtao, Email: sohoto@vip.163.com

Keywords：

Warfarin; mechanical heart valve replacement surgery; anticoagulation management; clinical pharmacist

DOI：

10.7507/1007-4848.201603072

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the role of clinical pharmacists in warfarin therapy. Methods A total of 134 patients underwent prosthetic heart valve replacement and had warfarin for life from March 2013 to October 2013 in Fujian Medical University Union Hospital. All patients were equally divided into two groups (an intervention and a non-intervention group) crosswise by sequence. There were 67 patients in each group. The anticoagulant effects of the two groups were compared. Results There was no statistical difference in the patients' demographic information between the two groups. However, the time for the patients to reach the target international normalized ratio(INR) values for the first time (7.1±3.3 dvs. 10.5±5.0 d,P=0.000) and time of INR in the therapy range (46.3%±18.8%vs.19.0%±16.2%,P=0.000) during their hospitalization, proportion of time of under anticoagulation (47.5%±19.5%vs. 71.2%±22.9%,P=0.000), proportion of time of anticoagulation overdose (5.3%±8.2%vs. 9.9%±16.7%,P=0.002) were significantly different. While there was no statistical difference in postoperative hospitalization time between the two groups (19.9±6.6 dvs. 18.1±7.0 d,P=0.137). There were 4 patients (6.0%) with minor hemorrhage and no severe complication was found in the intervention group. There were seven patients (10.4%) with mild hemorrhage, two patients with stroke, one patient with mild pulmonary embolism, and severe complication rate of 4.5% in the non-intervention group. Conclusion With clinical pharmacists involved in the whole anticoagulation therapy progress of patients after mechanical heart valve replacement, the time to achieve the therapeutic window for the first time is effectively shorten, and the time of the INR value controlled in therapeutic range is highly improved during hospitalization time. Moreover, the patients' risk of thrombosis and bleeding is eventually reduced.

Citation： LIN Meiqin, QIU Hanfan, XIE Xianbiao, CHEN Meilian, SONG Hongtao. Anticoagulation management in patients with mechanical heart valve replacement: A case control study. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2017, 24(4): 285-289. doi: 10.7507/1007-4848.201603072 Copy

1.	?黃雪珊, 陳道中, 廖崇先, 等. 人工機械瓣膜置換術 50 例抗凝治療隨訪. 福建醫科大學學報, 2003, 37(2): 224-226.
2.	張小飛, 肖亦敏, 程云閣, 等. 心臟機械瓣膜置換術后華法林低強度抗凝治療的臨床分析. 中國胸心血管外科臨床雜志, 2014, 21(2): 270-271.
3.	朱志成, 李丹, 王天策, 等. 東北人群人工機械瓣膜置換術后低強度抗凝治療的單中心研究. 中國胸心血管外科臨床雜志, 2014, 21(2): 160-163.
4.	The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med, 2009, 360(8): 753-764.
5.	Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med, 2013, 369(24): 2283-2293.
6.	Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med, 2013, 369(24): 2294-2303.
7.	Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med, 2013, 369(24): 2345-2346.
8.	Elewal H, Jalali F, Khudair N, et al. Evaluation of pharmacist-based compared to doctor-based anticoagulation management in Qatar. J Eval Clin Pract, 2016, 22(3): 433-438.
9.	Entezari-Maleki T, Dousti S, Hamishehkar H, et al. A systematic review on comparing 2 common models for management of warfarin therapy: pharmacist-led service versus usual medical care. J Clin Pharmacol, 2016, 56(1): 24-38.
10.	Bishop L, Young S, Twells L, et al. Patients’ and physicians’ satisfaction with a pharmacist managed anticoagulation program in a family medicine clinic. BMC Res Notes, 2015, 8: 233.
11.	Young S, Bishop L, Twells L, et al. Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. BMC Family Practice, 2011, 12: 88.
12.	Hicho MD, Rybarczyk A, Boros M. Interventions unrelated to anticoagulation in a pharmacist-managed anticoagulation clinic. Am J Health-Syst Pharm, 2016, 73(3): S80-S87.
13.	中華醫學會心血管病學分會、中國老年學學會心腦血管病專業委員會. 華法林抗凝治療的中國專家共識. 中華內科雜志, 2013, 52(1): 76-82.
14.	Lane MA, Zeringue A, McDonald JR. Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. Am J Med, 2014, 127(7): 657-663.
15.	Arnold LM, Nissen LR, Ng TM. Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction. Pharmacotherapy, 2005, 25(6): 904-907.
16.	Yamamoto H, Habu Y, Yano I, et al. Comparison of the effects of azole antifungal agents on the anticoagulant activity of warfarin. Biol Pharm Bull, 2014, 37(12): 1990-1993.
17.	Danie LM, Barreto JN, Kuth JC, et al. Failure mode and effects analysis to reduce risk of anticoagulation levels above the target range during concurrent antimicrobial therapy. Am J Health-Syst Pharm, 2015, 72(14): 1195-1203.
18.	McEwen BJ. The influence of herbal medicine on platelet function and coagulation: a narrative review. Semin Thromb Hemost, 2015, 41(3): 300-314.
19.	Tsai HH, Lin HW, Lu YH, et al. A review of potential harmful interactions between anticoagulant/antiplatelet agents and chinese herbal medicines. Plos One, 2013, 8(5): e64255.
20.	Chua YT, Ang XL, Zhong XM, et al. Interaction between warfarin and Chinese herbal medicines. Singapore Med J, 2015, 56(1): 11-18.

1. ?黃雪珊, 陳道中, 廖崇先, 等. 人工機械瓣膜置換術 50 例抗凝治療隨訪. 福建醫科大學學報, 2003, 37(2): 224-226.
2. 張小飛, 肖亦敏, 程云閣, 等. 心臟機械瓣膜置換術后華法林低強度抗凝治療的臨床分析. 中國胸心血管外科臨床雜志, 2014, 21(2): 270-271.
3. 朱志成, 李丹, 王天策, 等. 東北人群人工機械瓣膜置換術后低強度抗凝治療的單中心研究. 中國胸心血管外科臨床雜志, 2014, 21(2): 160-163.
4. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med, 2009, 360(8): 753-764.
5. Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med, 2013, 369(24): 2283-2293.
6. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med, 2013, 369(24): 2294-2303.
7. Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med, 2013, 369(24): 2345-2346.
8. Elewal H, Jalali F, Khudair N, et al. Evaluation of pharmacist-based compared to doctor-based anticoagulation management in Qatar. J Eval Clin Pract, 2016, 22(3): 433-438.
9. Entezari-Maleki T, Dousti S, Hamishehkar H, et al. A systematic review on comparing 2 common models for management of warfarin therapy: pharmacist-led service versus usual medical care. J Clin Pharmacol, 2016, 56(1): 24-38.
10. Bishop L, Young S, Twells L, et al. Patients’ and physicians’ satisfaction with a pharmacist managed anticoagulation program in a family medicine clinic. BMC Res Notes, 2015, 8: 233.
11. Young S, Bishop L, Twells L, et al. Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. BMC Family Practice, 2011, 12: 88.
12. Hicho MD, Rybarczyk A, Boros M. Interventions unrelated to anticoagulation in a pharmacist-managed anticoagulation clinic. Am J Health-Syst Pharm, 2016, 73(3): S80-S87.
13. 中華醫學會心血管病學分會、中國老年學學會心腦血管病專業委員會. 華法林抗凝治療的中國專家共識. 中華內科雜志, 2013, 52(1): 76-82.
14. Lane MA, Zeringue A, McDonald JR. Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. Am J Med, 2014, 127(7): 657-663.
15. Arnold LM, Nissen LR, Ng TM. Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction. Pharmacotherapy, 2005, 25(6): 904-907.
16. Yamamoto H, Habu Y, Yano I, et al. Comparison of the effects of azole antifungal agents on the anticoagulant activity of warfarin. Biol Pharm Bull, 2014, 37(12): 1990-1993.
17. Danie LM, Barreto JN, Kuth JC, et al. Failure mode and effects analysis to reduce risk of anticoagulation levels above the target range during concurrent antimicrobial therapy. Am J Health-Syst Pharm, 2015, 72(14): 1195-1203.
18. McEwen BJ. The influence of herbal medicine on platelet function and coagulation: a narrative review. Semin Thromb Hemost, 2015, 41(3): 300-314.
19. Tsai HH, Lin HW, Lu YH, et al. A review of potential harmful interactions between anticoagulant/antiplatelet agents and chinese herbal medicines. Plos One, 2013, 8(5): e64255.
20. Chua YT, Ang XL, Zhong XM, et al. Interaction between warfarin and Chinese herbal medicines. Singapore Med J, 2015, 56(1): 11-18.

Previous Article
Risk factors for sternal wound infection after various cardiac operations
Next Article
Minimally invasive sternal depression by autologous force for pectus carinatum repair

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Anticoagulation management in patients with mechanical heart valve replacement: A case control study

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content